Skip to main content
Erschienen in: Medical Oncology 8/2016

01.08.2016 | Original Paper

Metronomic cyclophosphamide therapy in hormone-naive patients with non-metastatic biochemical recurrent prostate cancer: a phase II trial

verfasst von: Fabien Calcagno, Guillaume Mouillet, Olivier Adotevi, Tristan Maurina, Thierry Nguyen, Philippe Montcuquet, E. Curtit, F. Kleinclauss, Xavier Pivot, Christophe Borg, Antoine Thiery-Vuillemin

Erschienen in: Medical Oncology | Ausgabe 8/2016

Einloggen, um Zugang zu erhalten

Abstract

After curative local therapy, biochemical recurrence is a mode of relapse among patient with prostate cancer (PC). Deferring androgen deprivation therapy (ADT) or offering non-hormonal therapies may be an appropriate option for these non-symptomatic patients with no proven metastases. Metronomic cyclophosphamide (MC) has shown activity in metastatic PC setting and was chosen to be assessed in biochemical relapse. This prospective single-arm open-label phase II study was conducted to evaluate MC regimen in patients with biochemical recurrent PC. MC was planned to be administered orally at a daily dose of 50 mg for 6 months. Primary endpoint was PSA response. Thirty-eight patients were included and treated. Median follow-up was 45.5 months (range 17–100). Among them, 14 patients (37 %) achieved PSA stabilisation and 22 patients (58 %) experienced PSA progression. Response rate was 5 % with one complete response (2.6 %), and 1 partial response with PSA decrease >50 % (2.6 %). The median time until androgen deprivation therapy initiation was around 15 months. The treatment was well tolerated. Neither grade 3–4 toxicity nor serious adverse events were observed. This first prospective clinical trial with MC therapy in patients with non-metastatic biochemical recurrence of PC displayed modest efficacy when measured with PSA response rate, without significant toxicity. It might offer a new safe and non-expensive option to delay initiation of ADT. These results would need to be confirmed with larger prospective randomised trials.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin. 2010;60(5):277–300.CrossRefPubMed Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin. 2010;60(5):277–300.CrossRefPubMed
2.
Zurück zum Zitat La Vecchia C, Bosetti C, Lucchini F, Bertuccio P, Negri E, Boyle P, et al. Cancer mortality in Europe, 2000–2004, and an overview of trends since 1975. Ann Oncol. 2010;21(6):1323–60.CrossRefPubMed La Vecchia C, Bosetti C, Lucchini F, Bertuccio P, Negri E, Boyle P, et al. Cancer mortality in Europe, 2000–2004, and an overview of trends since 1975. Ann Oncol. 2010;21(6):1323–60.CrossRefPubMed
3.
Zurück zum Zitat Khan MA, Han M, Partin AW, Epstein JI, Walsh PC. Long-term cancer control of radical prostatectomy in men younger than 50 years of age: update 2003. Urology. 2003;62(1):86–91 (discussion-2).CrossRefPubMed Khan MA, Han M, Partin AW, Epstein JI, Walsh PC. Long-term cancer control of radical prostatectomy in men younger than 50 years of age: update 2003. Urology. 2003;62(1):86–91 (discussion-2).CrossRefPubMed
4.
Zurück zum Zitat Djavan B, Moul JW, Zlotta A, Remzi M, Ravery V. PSA progression following radical prostatectomy and radiation therapy: new standards in the new Millennium. Eur Urol. 2003;43(1):12–27.CrossRefPubMed Djavan B, Moul JW, Zlotta A, Remzi M, Ravery V. PSA progression following radical prostatectomy and radiation therapy: new standards in the new Millennium. Eur Urol. 2003;43(1):12–27.CrossRefPubMed
5.
Zurück zum Zitat Polascik TJ, Oesterling JE, Partin AW. Prostate specific antigen: a decade of discovery–what we have learned and where we are going. J Urol. 1999;162(2):293–306.CrossRefPubMed Polascik TJ, Oesterling JE, Partin AW. Prostate specific antigen: a decade of discovery–what we have learned and where we are going. J Urol. 1999;162(2):293–306.CrossRefPubMed
6.
Zurück zum Zitat Moul JW. Prostate specific antigen only progression of prostate cancer. J Urol. 2000;163(6):1632–42.CrossRefPubMed Moul JW. Prostate specific antigen only progression of prostate cancer. J Urol. 2000;163(6):1632–42.CrossRefPubMed
7.
Zurück zum Zitat Pound CR, Partin AW, Eisenberger MA, Chan DW, Pearson JD, Walsh PC. Natural history of progression after PSA elevation following radical prostatectomy. JAMA. 1999;281(17):1591–7.CrossRefPubMed Pound CR, Partin AW, Eisenberger MA, Chan DW, Pearson JD, Walsh PC. Natural history of progression after PSA elevation following radical prostatectomy. JAMA. 1999;281(17):1591–7.CrossRefPubMed
8.
Zurück zum Zitat Roach M 3rd, Hanks G, Thames H Jr, Schellhammer P, Shipley WU, Sokol GH, et al. Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO Phoenix Consensus Conference. Int J Radiat Oncol Biol Phys. 2006;65(4):965–74.CrossRefPubMed Roach M 3rd, Hanks G, Thames H Jr, Schellhammer P, Shipley WU, Sokol GH, et al. Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO Phoenix Consensus Conference. Int J Radiat Oncol Biol Phys. 2006;65(4):965–74.CrossRefPubMed
9.
Zurück zum Zitat Andre N, Carre M, Pasquier E. Metronomics: towards personalized chemotherapy? Nat Rev Clin Oncol. 2014;11(7):413–31.CrossRefPubMed Andre N, Carre M, Pasquier E. Metronomics: towards personalized chemotherapy? Nat Rev Clin Oncol. 2014;11(7):413–31.CrossRefPubMed
10.
Zurück zum Zitat Gnoni A, Silvestris N, Licchetta A, Santini D, Scartozzi M, Ria R, et al. Metronomic chemotherapy from rationale to clinical studies: a dream or reality? Crit Rev Oncol Hematol. 2015;95(1):46–61.CrossRefPubMed Gnoni A, Silvestris N, Licchetta A, Santini D, Scartozzi M, Ria R, et al. Metronomic chemotherapy from rationale to clinical studies: a dream or reality? Crit Rev Oncol Hematol. 2015;95(1):46–61.CrossRefPubMed
11.
Zurück zum Zitat Andre N, Padovani L, Verschuur A. Metronomic chemotherapy: back to the future! Drug News Perspect. 2010;23(2):143–51.CrossRefPubMed Andre N, Padovani L, Verschuur A. Metronomic chemotherapy: back to the future! Drug News Perspect. 2010;23(2):143–51.CrossRefPubMed
12.
Zurück zum Zitat Lien K, Georgsdottir S, Sivanathan L, Chan K, Emmenegger U. Low-dose metronomic chemotherapy: a systematic literature analysis. Eur J Cancer. 2013;49(16):3387–95.CrossRefPubMed Lien K, Georgsdottir S, Sivanathan L, Chan K, Emmenegger U. Low-dose metronomic chemotherapy: a systematic literature analysis. Eur J Cancer. 2013;49(16):3387–95.CrossRefPubMed
13.
Zurück zum Zitat Yashi M, Nishihara D, Mizuno T, Yuki H, Masuda A, Kambara T, et al. Metronomic oral cyclophosphamide chemotherapy possibly contributes to stabilization of disease in patients with metastatic castration-resistant prostate cancer: a prospective analysis of consecutive cases. Clin Genitourin Cancer. 2014;12(5):e197–203.CrossRefPubMed Yashi M, Nishihara D, Mizuno T, Yuki H, Masuda A, Kambara T, et al. Metronomic oral cyclophosphamide chemotherapy possibly contributes to stabilization of disease in patients with metastatic castration-resistant prostate cancer: a prospective analysis of consecutive cases. Clin Genitourin Cancer. 2014;12(5):e197–203.CrossRefPubMed
14.
Zurück zum Zitat Ladoire S, Eymard JC, Zanetta S, Mignot G, Martin E, Kermarrec I, et al. Metronomic oral cyclophosphamide prednisolone chemotherapy is an effective treatment for metastatic hormone-refractory prostate cancer after docetaxel failure. Anticancer Res. 2010;30(10):4317–23.PubMed Ladoire S, Eymard JC, Zanetta S, Mignot G, Martin E, Kermarrec I, et al. Metronomic oral cyclophosphamide prednisolone chemotherapy is an effective treatment for metastatic hormone-refractory prostate cancer after docetaxel failure. Anticancer Res. 2010;30(10):4317–23.PubMed
15.
Zurück zum Zitat Lord R, Nair S, Schache A, Spicer J, Somaihah N, Khoo V, et al. Low dose metronomic oral cyclophosphamide for hormone resistant prostate cancer: a phase II study. J Urol. 2007;177(6):2136–40 (discussion 40).CrossRefPubMed Lord R, Nair S, Schache A, Spicer J, Somaihah N, Khoo V, et al. Low dose metronomic oral cyclophosphamide for hormone resistant prostate cancer: a phase II study. J Urol. 2007;177(6):2136–40 (discussion 40).CrossRefPubMed
16.
Zurück zum Zitat Nicolini A, Mancini P, Ferrari P, Anselmi L, Tartarelli G, Bonazzi V, et al. Oral low-dose cyclophosphamide in metastatic hormone refractory prostate cancer (MHRPC). Biomed Pharmacother. 2004;58(8):447–50.CrossRefPubMed Nicolini A, Mancini P, Ferrari P, Anselmi L, Tartarelli G, Bonazzi V, et al. Oral low-dose cyclophosphamide in metastatic hormone refractory prostate cancer (MHRPC). Biomed Pharmacother. 2004;58(8):447–50.CrossRefPubMed
17.
Zurück zum Zitat Raghavan D, Cox K, Pearson BS, Coorey GJ, Rogers J, Watt WH, et al. Oral cyclophosphamide for the management of hormone-refractory prostate cancer. Br J Urol. 1993;72(5 Pt 1):625–8.CrossRefPubMed Raghavan D, Cox K, Pearson BS, Coorey GJ, Rogers J, Watt WH, et al. Oral cyclophosphamide for the management of hormone-refractory prostate cancer. Br J Urol. 1993;72(5 Pt 1):625–8.CrossRefPubMed
18.
Zurück zum Zitat Derosa L, Galli L, Orlandi P, Fioravanti A, Di Desidero T, Fontana A, et al. Docetaxel plus oral metronomic cyclophosphamide: a phase II study with pharmacodynamic and pharmacogenetic analyses in castration-resistant prostate cancer patients. Cancer. 2014;120(24):3923–31.CrossRefPubMed Derosa L, Galli L, Orlandi P, Fioravanti A, Di Desidero T, Fontana A, et al. Docetaxel plus oral metronomic cyclophosphamide: a phase II study with pharmacodynamic and pharmacogenetic analyses in castration-resistant prostate cancer patients. Cancer. 2014;120(24):3923–31.CrossRefPubMed
19.
Zurück zum Zitat Barroso-Sousa R, da Fonseca LG, Souza KT, Chaves AC, Kann AG, de Castro G Jr, et al. Metronomic oral cyclophosphamide plus prednisone in docetaxel-pretreated patients with metastatic castration-resistant prostate cancer. Med Oncol. 2015;32(1):443.CrossRefPubMed Barroso-Sousa R, da Fonseca LG, Souza KT, Chaves AC, Kann AG, de Castro G Jr, et al. Metronomic oral cyclophosphamide plus prednisone in docetaxel-pretreated patients with metastatic castration-resistant prostate cancer. Med Oncol. 2015;32(1):443.CrossRefPubMed
20.
Zurück zum Zitat Orlandi P, Fontana A, Fioravanti A, Di Desidero T, Galli L, Derosa L, et al. VEGF-A polymorphisms predict progression-free survival among advanced castration-resistant prostate cancer patients treated with metronomic cyclophosphamide. Br J Cancer. 2013;109(4):957–64.CrossRefPubMedPubMedCentral Orlandi P, Fontana A, Fioravanti A, Di Desidero T, Galli L, Derosa L, et al. VEGF-A polymorphisms predict progression-free survival among advanced castration-resistant prostate cancer patients treated with metronomic cyclophosphamide. Br J Cancer. 2013;109(4):957–64.CrossRefPubMedPubMedCentral
21.
Zurück zum Zitat Dickinson PD, Peel DN, Sundar S. Metronomic chemotherapy with cyclophosphamide and dexamethasone in patients with metastatic carcinoma of the prostate. Br J Cancer. 2012;106(8):1464–5 (author reply 6).CrossRefPubMedPubMedCentral Dickinson PD, Peel DN, Sundar S. Metronomic chemotherapy with cyclophosphamide and dexamethasone in patients with metastatic carcinoma of the prostate. Br J Cancer. 2012;106(8):1464–5 (author reply 6).CrossRefPubMedPubMedCentral
22.
Zurück zum Zitat Meng LJ, Wang J, Fan WF, Pu XL, Liu FY, Yang M. Evaluation of oral chemotherapy with capecitabine and cyclophosphamide plus thalidomide and prednisone in prostate cancer patients. J Cancer Res Clin Oncol. 2012;138(2):333–9.CrossRefPubMed Meng LJ, Wang J, Fan WF, Pu XL, Liu FY, Yang M. Evaluation of oral chemotherapy with capecitabine and cyclophosphamide plus thalidomide and prednisone in prostate cancer patients. J Cancer Res Clin Oncol. 2012;138(2):333–9.CrossRefPubMed
23.
Zurück zum Zitat Hatano K, Nonomura N, Nishimura K, Kawashima A, Mukai M, Nagahara A, et al. Retrospective analysis of an oral combination of dexamethasone, uracil plus tegafur and cyclophosphamide for hormone-refractory prostate cancer. Jpn J Clin Oncol. 2011;41(2):253–9.CrossRefPubMed Hatano K, Nonomura N, Nishimura K, Kawashima A, Mukai M, Nagahara A, et al. Retrospective analysis of an oral combination of dexamethasone, uracil plus tegafur and cyclophosphamide for hormone-refractory prostate cancer. Jpn J Clin Oncol. 2011;41(2):253–9.CrossRefPubMed
24.
Zurück zum Zitat Gebbia V, Serretta V, Borsellino N, Valerio MR, Foundation G. Salvage therapy with oral metronomic cyclophosphamide and methotrexate for castration-refractory metastatic adenocarcinoma of the prostate resistant to docetaxel. Urology. 2011;78(5):1125–30.CrossRefPubMed Gebbia V, Serretta V, Borsellino N, Valerio MR, Foundation G. Salvage therapy with oral metronomic cyclophosphamide and methotrexate for castration-refractory metastatic adenocarcinoma of the prostate resistant to docetaxel. Urology. 2011;78(5):1125–30.CrossRefPubMed
25.
Zurück zum Zitat Jellvert A, Lissbrant IF, Edgren M, Ovferholm E, Braide K, Olvenmark AM, et al. Effective oral combination metronomic chemotherapy with low toxicity for the management of castration-resistant prostate cancer. Exp Ther Med. 2011;2(4):579–84.PubMedPubMedCentral Jellvert A, Lissbrant IF, Edgren M, Ovferholm E, Braide K, Olvenmark AM, et al. Effective oral combination metronomic chemotherapy with low toxicity for the management of castration-resistant prostate cancer. Exp Ther Med. 2011;2(4):579–84.PubMedPubMedCentral
26.
Zurück zum Zitat Fontana A, Galli L, Fioravanti A, Orlandi P, Galli C, Landi L, et al. Clinical and pharmacodynamic evaluation of metronomic cyclophosphamide, celecoxib, and dexamethasone in advanced hormone-refractory prostate cancer. Clin Cancer Res. 2009;15(15):4954–62.CrossRefPubMed Fontana A, Galli L, Fioravanti A, Orlandi P, Galli C, Landi L, et al. Clinical and pharmacodynamic evaluation of metronomic cyclophosphamide, celecoxib, and dexamethasone in advanced hormone-refractory prostate cancer. Clin Cancer Res. 2009;15(15):4954–62.CrossRefPubMed
27.
Zurück zum Zitat Nelius T, Klatte T, de Riese W, Haynes A, Filleur S. Clinical outcome of patients with docetaxel-resistant hormone-refractory prostate cancer treated with second-line cyclophosphamide-based metronomic chemotherapy. Med Oncol. 2010;27(2):363–7.CrossRefPubMed Nelius T, Klatte T, de Riese W, Haynes A, Filleur S. Clinical outcome of patients with docetaxel-resistant hormone-refractory prostate cancer treated with second-line cyclophosphamide-based metronomic chemotherapy. Med Oncol. 2010;27(2):363–7.CrossRefPubMed
28.
Zurück zum Zitat Di Lorenzo G, Autorino R, De Laurentiis M, Forestieri V, Romano C, Prudente A, et al. Thalidomide in combination with oral daily cyclophosphamide in patients with pretreated hormone refractory prostate cancer: a phase I clinical trial. Cancer Biol Ther. 2007;6(3):313–7.CrossRefPubMed Di Lorenzo G, Autorino R, De Laurentiis M, Forestieri V, Romano C, Prudente A, et al. Thalidomide in combination with oral daily cyclophosphamide in patients with pretreated hormone refractory prostate cancer: a phase I clinical trial. Cancer Biol Ther. 2007;6(3):313–7.CrossRefPubMed
29.
Zurück zum Zitat Hellerstedt B, Pienta KJ, Redman BG, Esper P, Dunn R, Fardig J, et al. Phase II trial of oral cyclophosphamide, prednisone, and diethylstilbestrol for androgen-independent prostate carcinoma. Cancer. 2003;98(8):1603–10.CrossRefPubMed Hellerstedt B, Pienta KJ, Redman BG, Esper P, Dunn R, Fardig J, et al. Phase II trial of oral cyclophosphamide, prednisone, and diethylstilbestrol for androgen-independent prostate carcinoma. Cancer. 2003;98(8):1603–10.CrossRefPubMed
30.
Zurück zum Zitat Glode LM, Barqawi A, Crighton F, Crawford ED, Kerbel R. Metronomic therapy with cyclophosphamide and dexamethasone for prostate carcinoma. Cancer. 2003;98(8):1643–8.CrossRefPubMed Glode LM, Barqawi A, Crighton F, Crawford ED, Kerbel R. Metronomic therapy with cyclophosphamide and dexamethasone for prostate carcinoma. Cancer. 2003;98(8):1643–8.CrossRefPubMed
31.
Zurück zum Zitat Nishimura K, Nonomura N, Ono Y, Nozawa M, Fukui T, Harada Y, et al. Oral combination of cyclophosphamide, uracil plus tegafur and estramustine for hormone-refractory prostate cancer. Oncology. 2001;60(1):49–54.CrossRefPubMed Nishimura K, Nonomura N, Ono Y, Nozawa M, Fukui T, Harada Y, et al. Oral combination of cyclophosphamide, uracil plus tegafur and estramustine for hormone-refractory prostate cancer. Oncology. 2001;60(1):49–54.CrossRefPubMed
32.
Zurück zum Zitat Bracarda S, Tonato M, Rosi P, De Angelis V, Mearini E, Cesaroni S, et al. Oral estramustine and cyclophosphamide in patients with metastatic hormone refractory prostate carcinoma: a phase II study. Cancer. 2000;88(6):1438–44.CrossRefPubMed Bracarda S, Tonato M, Rosi P, De Angelis V, Mearini E, Cesaroni S, et al. Oral estramustine and cyclophosphamide in patients with metastatic hormone refractory prostate carcinoma: a phase II study. Cancer. 2000;88(6):1438–44.CrossRefPubMed
33.
Zurück zum Zitat Maulard-Durdux C, Dufour B, Hennequin C, Chretien Y, Delanian S, Housset M. Phase II study of the oral cyclophosphamide and oral etoposide combination in hormone-refractory prostate carcinoma patients. Cancer. 1996;77(6):1144–8.CrossRefPubMed Maulard-Durdux C, Dufour B, Hennequin C, Chretien Y, Delanian S, Housset M. Phase II study of the oral cyclophosphamide and oral etoposide combination in hormone-refractory prostate carcinoma patients. Cancer. 1996;77(6):1144–8.CrossRefPubMed
34.
Zurück zum Zitat Wozniak AJ, Blumenstein BA, Crawford ED, Boileau M, Rivkin SE, Fletcher WS. Cyclophosphamide, methotrexate, and 5-fluorouracil in the treatment of metastatic prostate cancer. A Southwest Oncology Group study. Cancer. 1993;71(12):3975–8.CrossRefPubMed Wozniak AJ, Blumenstein BA, Crawford ED, Boileau M, Rivkin SE, Fletcher WS. Cyclophosphamide, methotrexate, and 5-fluorouracil in the treatment of metastatic prostate cancer. A Southwest Oncology Group study. Cancer. 1993;71(12):3975–8.CrossRefPubMed
37.
Zurück zum Zitat Duchesne GM, Woo HH, Bassett JK, Bowe SJ, D’Este C, Frydenberg M, et al. Timing of androgen-deprivation therapy in patients with prostate cancer with a rising PSA (TROG 03.06 and VCOG PR 01-03 [TOAD]): a randomised, multicentre, non-blinded, phase 3 trial. Lancet Oncol. 2016;17(6):727–37.CrossRefPubMed Duchesne GM, Woo HH, Bassett JK, Bowe SJ, D’Este C, Frydenberg M, et al. Timing of androgen-deprivation therapy in patients with prostate cancer with a rising PSA (TROG 03.06 and VCOG PR 01-03 [TOAD]): a randomised, multicentre, non-blinded, phase 3 trial. Lancet Oncol. 2016;17(6):727–37.CrossRefPubMed
38.
Zurück zum Zitat Xabier Garcia-Albeniz JMC, Paciorek AT, Logan RW, Kenfield SA, Cooperberg MR, Caroll P, Hernan M. Immediate versus deferred initiation of androgen deprivation therapy in prostate cancer patients with PSA-only relapse. J Clin Oncol 32:5s, 2014 (suppl; abstr 5003). In: 2014 ASCO Annual Meeting. 2014; Oral Abstract Session, Genitourinary (Prostate) Cancer(5003). Xabier Garcia-Albeniz JMC, Paciorek AT, Logan RW, Kenfield SA, Cooperberg MR, Caroll P, Hernan M. Immediate versus deferred initiation of androgen deprivation therapy in prostate cancer patients with PSA-only relapse. J Clin Oncol 32:5s, 2014 (suppl; abstr 5003). In: 2014 ASCO Annual Meeting. 2014; Oral Abstract Session, Genitourinary (Prostate) Cancer(5003).
39.
Zurück zum Zitat Crook JM, O’Callaghan CJ, Duncan G, Dearnaley DP, Higano CS, Horwitz EM, et al. Intermittent androgen suppression for rising PSA level after radiotherapy. N Engl J Med. 2012;367(10):895–903.CrossRefPubMedPubMedCentral Crook JM, O’Callaghan CJ, Duncan G, Dearnaley DP, Higano CS, Horwitz EM, et al. Intermittent androgen suppression for rising PSA level after radiotherapy. N Engl J Med. 2012;367(10):895–903.CrossRefPubMedPubMedCentral
40.
Zurück zum Zitat Andres E, Eschwege P, Lang H, Moreau JL, Peiffert D, Thiery-Vuillemin A, et al. Metabolic impact of androgen deprivation therapy for prostate cancer. Prog Urol. 2012;22(Suppl 2):S39–47.CrossRefPubMed Andres E, Eschwege P, Lang H, Moreau JL, Peiffert D, Thiery-Vuillemin A, et al. Metabolic impact of androgen deprivation therapy for prostate cancer. Prog Urol. 2012;22(Suppl 2):S39–47.CrossRefPubMed
Metadaten
Titel
Metronomic cyclophosphamide therapy in hormone-naive patients with non-metastatic biochemical recurrent prostate cancer: a phase II trial
verfasst von
Fabien Calcagno
Guillaume Mouillet
Olivier Adotevi
Tristan Maurina
Thierry Nguyen
Philippe Montcuquet
E. Curtit
F. Kleinclauss
Xavier Pivot
Christophe Borg
Antoine Thiery-Vuillemin
Publikationsdatum
01.08.2016
Verlag
Springer US
Erschienen in
Medical Oncology / Ausgabe 8/2016
Print ISSN: 1357-0560
Elektronische ISSN: 1559-131X
DOI
https://doi.org/10.1007/s12032-016-0806-0

Weitere Artikel der Ausgabe 8/2016

Medical Oncology 8/2016 Zur Ausgabe

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.